Brokerages Set Haemonetics Corporation (NYSE:HAE) PT at $78.78

Haemonetics Corporation (NYSE:HAE) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $78.7778.

Several equities analysts have issued reports on HAE shares. Needham & Company LLC reiterated a “buy” rating and issued a $68.00 price objective (down previously from $84.00) on shares of Haemonetics in a research report on Thursday, August 7th. Robert W. Baird initiated coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an “outperform” rating and a $87.00 price target on the stock. JPMorgan Chase & Co. restated a “neutral” rating and issued a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Citigroup upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and set a $90.00 target price on the stock in a research report on Wednesday, July 9th. Finally, Raymond James Financial cut shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and decreased their price target for the company from $105.00 to $78.00 in a research note on Monday, August 11th.

Haemonetics Stock Up 1.1%

HAE opened at $48.20 on Monday. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of 14.74, a PEG ratio of 0.89 and a beta of 0.39. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. The firm’s 50-day simple moving average is $58.73 and its 200-day simple moving average is $64.23. Haemonetics has a twelve month low of $47.31 and a twelve month high of $94.99.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.09. The firm had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. Equities research analysts anticipate that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Quarry LP boosted its stake in Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 192 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares during the period. GAMMA Investing LLC grew its position in shares of Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 165 shares during the period. UMB Bank n.a. raised its position in shares of Haemonetics by 91.7% in the 2nd quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 320 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new position in Haemonetics during the 2nd quarter worth approximately $64,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.